Abstract

By virtual screening, compound <b>1</b> was found to be active against NS2B-NS3 protease (IC<sub>50</sub> = 13.12 ± 1.03 μM). Fourteen derivatives (<b>22</b>) of compound <b>1</b> were synthesized, leading to the discovery of four new inhibitors with biological activity. In order to expand the chemical diversity of the inhibitors, small-molecule-based scaffold hopping was performed on the basis of the common scaffold of compounds <b>1</b> and <b>22</b>. Twenty-one new compounds (<b>23</b>, <b>24</b>) containing quinoline (new scaffold) were designed and synthesized. Protease inhibition assays revealed that 12 compounds with the new scaffold are inhibitors of NS2B-NS3 protease. Taken together, 17 new compounds were discovered as NS2B-NS3 protease inhibitors with IC<sub>50</sub> values of 7.46 ± 1.15 to 48.59 ± 3.46 μM, and 8 compounds belonging to two different scaffolds are active to some extent against DENV based on luciferase reporter replicon-based assays. These novel chemical entities could serve as lead structures for discovering therapies against DENV

    Similar works

    Full text

    thumbnail-image

    Available Versions